Pharmacological approaches to counter the toxicity of dopa

Amino Acids

Volumn 14, Issue 1-3, 1998, Pages 189-196

  VonVoigtlander, P F ^a   Fici, G J ^a   Althaus, J S ^a  

^a PFIZER INC   (United States)

Author keywords

Antioxidant; Deprenyl; Neurotoxicity; Parkinson's disease; Pramipexole; Pyrroloprimidine; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ANTIPARKINSON AGENT; CATALASE; DOPA; DOPAMINE RECEPTOR; GLUTATHIONE; LEVODOPA; NEUROPROTECTIVE AGENT; NEUROTOXIN; PNU 101033; PRAMIPEXOLE; SELEGILINE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; CONFERENCE PAPER; CONTROLLED STUDY; GRANULE CELL; NERVE CELL CULTURE; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; BENZOTHIAZOLES; CELLS, CULTURED; CEREBELLUM; CYTOPLASMIC GRANULES; GLUTATHIONE; LEVODOPA; NEUROPROTECTIVE AGENTS; PYRIMIDINES; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; SELEGILINE; THIAZOLES; VITAMIN E;

ANIMALIA;

EID: 0031964353     PISSN: 09394451     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01345261     Document Type: Conference Paper

References (14)

1. Basma AN, Morris EJ, Nicklas WJ, Geller HM (1995) L-dopa cytotoxicity to PC12 cells in culture is via its autoxidation. J Neurochem 64: 825-832
2. 3 agonist pramipexole against post-ischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res 742: 80-88
3. Hall ED, Andrus PK, Smith SL, Fleck T, Scherch HM, Lutzke BS, Sawada GA, Althaus JS, VonVoigtlander PF, Padbury GE, Larson PG, Palmer JR, Bundy GL (1997) Pyrrolopyrimidines: novel brain-penetrating antioxidants with neuroprotective activity in brain injury and ischemia models. J Pharmacol Exp Ther 281: 895-904
4. 3H]dopamine: impact of ascorbic acid and glutathione. J Neurochem 63: 1126-1132
5. Ling ZD, Pieri SC, Carvey PM (1996) Comparison of the neurotoxicity of dihydroxyphenylalanine stereoisomers in cultured dopamine neurons. Clin Neuropharmacol 19: 360-365
6. Marsden CD, Parkes JD (1977) Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet i: 345-349
7. Neuschwander-Tetri BA, Roll FJ (1989) Glutathione measurement by high-performance liquid chromatography separation and fluorometric detection of the glutathione-orthopthalaldehyde adduct. Analytical Biochem 179: 236-241
8. Nicolletti F, Wroblewski JT, Novelli A, Alho H, Guidotti A, Costa E (1986) The activation of inositol phospholipid metabolism as a signal-transducing system for excitatory amino acids in primary cultures of cerebellar granule cells. J Neurosci 6: 1905-1911
9. Novelli A, Reilly JA, Lysko PG, Henneberry RC (1988) Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res 251: 205-212
10. Pardo B, Mena MA, Casarejos MJ, Paino CL, De-Yebenes JG (1995) Toxic effects of L-Dopa on mesencephalic cell cultures: protection with antioxidants. Brain Res 682: 133-143
11. Sian J, Dexter DT, Lees AJ, Daniels S, Jenner P, Marsden CD (1994) Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36: 356-361
12. Spencer JPE, Jenner P, Halliwell B (1995) Superoxide-dependent depletion of reduced glutathione by L-dopa and dopamine. Relevance to Parkinson's disease. Neuroreport 6: 1480-1484
13. Swerdlow RH, Parks JK, Miller SW, Tuttle JB, Trimmer PA, Sheehan JP, Bennett JP, Davis RE, Parker WD Jr (1996) Origin and functional consequences of the complex i defect in Parkinson's disease. Ann Neurol 40: 663-671
14. Walkinshaw G, Waters CM (1995) Induction of apoptosis in catecholaminergic PC12 cells by L-Dopa. Implications for the treatment of Parkinson's disease. J Clin Invest 95: 2458-2464